HER2low invasive breast cancer: Trastuzumab offers no improvement for invasive disease free survival

Adjuvant trastuzumab did not improve outcomes for patients with HER2-low breast cancer

Precision Panc, a platform for pancreatic cancer

A biological perspective for personalising immunotherapies

Personalised haematology treatments

The importance of increasing biomarker understanding

Bevacizumab and colorectal cancer in geriatrics

The promise of immunotherapy for elderly patients

Toxicities in treatments of lung cancers with respect to the elderly

Encouraging age related reviews of three new breast cancer treatments

Adoptive cell therapy for solid tumours

The next steps for effective cancer immunotherapy and viral vaccines